Vadastuximab talirine Completed Phase 1 Trials for Acute Myeloid Leukemia / Acute Promyelocytic Leukemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01902329A Safety Study of SGN-CD33A in AML Patients